N@N

Market Maker Surveillance Report. TGB, DRYS, XTLB, PME, ABAC, ITLL, Losing Stocks With Lowest Price Friction For Friday, Febru

February 17, 2017 / M2 PRESSWIRE / BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Friday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Friday there were 5684 companies with "abnormal" market making, 3067 companies with positive Friction Factors and 2760 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage loss per share Friday and low price friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. Taseko Mines Limited (NYSE:TGB), DryShips Inc. (NASDAQ:DRYS), XTL Biopharma (NASDAQ:XTLB), PreMD Inc. (NASDAQ:PME), Aoxin Tianli Group Inc. (NASDAQ:ABAC), INTELLIGENT MOTOR CR (OTC:ITLL). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .

Market Maker Friction Factor is shown in the chart below:

  Symbol  Change    Percent   Buy Volume   Buy %%    Sell Volume  Sell %%   Net Volume   Friction
  TGB     $-0.200   -0.13%    865,853      34.12%    910,894      35.90%    -45,041      -2,252  
  DRYS    $-0.680   -0.16%    4,007,319    40.89%    4,208,103    42.93%    -200,784     -2,953  
  XTLB    $-1.270   -0.36%    455,662      34.41%    582,884      44.02%    -127,222     -1,002  
  PME     $-0.830   -0.19%    432,543      28.59%    514,506      34.01%    -81,963      -988    
  ABAC    $-0.550   -0.17%    41,072       31.01%    54,371       41.05%    -13,299      -242    
  ITLL    $-0.218   -0.16%    100,429      38.46%    159,382      61.04%    -58,953      -2,708  

Analysis of the Friction Factor chart above shows that each of the six stocks mentioned above have high net dollar losses (Change) and extremely low price friction in their stocks. The Friction Factor displays how many more shares of buying than selling are required to move a stock higher by one cent or how many more shares of selling than buying moves a stock lower by 1 cent.

For example, the chart above shows TGB with a dollar loss Friday of $-0.20000 and a Friction Factor of -2,252 shares. That means that it only took 2,252 more shares of selling than buying to move TGB lower by one penny. This means the Market Makers are allowing the stock to drop quickly (low friction). The combination of low friction and negative market direction can drive prices lower faster than normal.

Taseko Mines Limited (NYSE:TGB) - Taseko Mines Limited, a mining company, acquires, develops, and operates mineral properties in Canada and the United States. The company explores for copper, molybdenum, gold, and niobium deposits. It holds a 75% interest the Gibraltar mine located in south-central British Columbia. The company also has interests in the Aley niobium, Harmony gold, and New Prosperity gold-copper projects situated in British Columbia; and the Florence copper project located in central Arizona. Taseko Mines Limited was founded in 1966 and is headquartered in Vancouver, Canada..

DryShips Inc. (NASDAQ:DRYS) - DryShips Inc. provides seaborne dry cargo and offshore support services. The company operates through Drybulk and Offshore Support segments. The Drybulk segment provides drybulk commodities transportation services for the steel, electric utility, construction, and agri-food industries. The Offshore Support segment offers its services to the global offshore energy industry. As of January 20, 2017, it owned a fleet of 13 Panamax drybulk carriers with a combined deadweight tonnage of approximately 1.0 million tons; and 6 offshore supply vessels comprising 2 platform supply and 4 oil spill recovery vessels, as well as 1 very large gas carrier newbuilding. The company was founded in 2004 and is based in Athens, Greece..

XTL Biopharma (NASDAQ:XTLB) - XTL Biopharmaceuticals Ltd., incorporated on March 9, 1993, is a biopharmaceutical company engaged in the acquisition, development and commercialization of pharmaceutical products for the treatment of infectious diseases, particularly the treatment of hepatitis C. The Company has four products/programs under development: XTL-2125, XTL-6865, diversity oriented Synthesis (DOS) and HepeX-B. XTL-2125 is a small molecule non-nucleoside, polymerase inhibitor for the treatment of patients with hepatitis C. XTL-6865 is a combination of two monoclonal antibodies against the hepatitis C virus. DOS is focused on the development of novel hepatitis C small molecule inhibitors. HepeX-B, is designed to prevent re-infection with hepatitis B in liver transplant patients.

The Company's Trimera technology is a method for introducing functional human cells or tissue into a mouse. The Trimera technology is a tool whereby murine immune systems are ablated by radiation, and bone marrow is transplanted from genetically immuno-deficient mice to re-enable red blood cell production. The result is the production of radiation chimeras. As these chimeras have no immune system, they are able to accept implanted human cells, without rejection, thereby creating a Trimera. The resulting mouse can be used to generate humanized monoclonal antibodies and as an animal model of human disease.

XTL-2125

XTL-2125 is being developed for the treatment of hepatitis C. XTL-2125 is an orally available non-nucleoside hepatitis C virus (HCV) ribonucleic acid RNA polymerase inhibitor. XTL-2125 has demonstrated potent activity against the hepatitis C virus in several pre-clinical systems. Investigational new drug (IND)-enabling GLP studies demonstrated that XTL-2125 has favorable oral pharmacokinetics and a good safety profile in multiple animal species. In May 2006, the Company announced the initiation of a Phase I, placebo-controlled, dose escalation trial of XTL-2125 in chronic HCV patients. The compound was in-licensed by the Company from B&C Biopharm Co., Ltd., a Korean drug development company. The Phase I trial is a placebo controlled, randomized, dose escalating study, which will evaluate the safety, tolerability and antiviral activity of single and multiple doses of XTL-2125. The study will enroll 48 patients into six cohorts comprised of eight patients each. Each patient will receive a single dose, followed by a 14-day multi-dosing regimen commencing one week after the single dose administration.

XTL-6865

XTL-6865 is also being developed for the treatment of hepatitis C. XTL-6865 (formerly known as the HepeX-C program) is a combination of two fully human monoclonal antibodies (Ab68 and Ab65) against the hepatitis C virus E2 envelope protein. A single antibody version of this product was tested in a pilot clinical program that included both Phase I and Phase II clinical trials. In April 2005, XTL Biopharmaceuticals Ltd. submitted an IND to the United States Food and drug Administration (FDA) in order to commence a Phase Ia/Ib clinical trial for XTL-6865, the dual-antibody product. In September 2005, the Company announced the initiation of a Phase Ia clinical trial with XTL-6865 in patients with chronic hepatitis C. The Phase Ia study is designed to evaluate the safety, tolerability, and virologic activity of escalating single doses of XTL-6865 in patients with chronic hepatitis C virus infection, and to assess the pharmacokinetics of XTL-6865 in the presence of viral infection.

DOS

DOS is a pre-clinical program focused on the development of hepatitis C small molecule inhibitors. Compounds developed to date inhibit HCV replication in a pre-clinical cell-based assay with potencies comparable to clinical stage drugs. These compounds are being optimized. The Company expects to identify the first clinical candidate from the DOS program and start IND-enabling GLP-safety studies with this clinical candidate in 2006.

HepeX-B

HepeX-B is being developed to prevent re-infection with hepatitis B, known as HBV, in liver transplant patients. H.

PreMD Inc. (NASDAQ:PME) - PreMD Inc., formerly IMI International Medical Innovations Inc., incorporated on November 9, 1992, is a predictive medicine company dedicated to improving health outcomes with non- or minimally invasive tools for the early detection of life-threatening diseases, particularly cardiovascular disease and cancer. The Company's products are designed to identify those patients at risk for disease. It is developing tests designed for use at the point of care, in the doctor's office, at the pharmacy and at home. The Company's pipeline of products includes coronary artery disease risk assessment technology, such as PREVU Point of Care (POC) Skin Sterol Test, PREVU LT Skin Sterol Test (lab-processed format), PREVU PT Skin Sterol Test (home, or consumer, format), and cancer technologies, such as ColorectAlert, LungAlert and breast cancer test.

Coronary Artery Disease Risk Assessment Technology

PREVU POC Skin Sterol Test, formerly known as Cholesterol 1,2,3, is a non-invasive test that evaluates the amount of cholesterol accumulated in a patient's epidermis (skin) surface. PREVU POC is packaged in a 20-test kit that contains three dropper bottles consisting of a binding solution, an indicator solution and a positive control, as well as 20 adhesive-backed pads. In addition, a hand-held instrument, which connects to a computer is used to measure the color change and provides a skin cholesterol value. The results of this test give an indication of the patient's coronary artery disease (CAD) risk. PREVU POC has a shelf life of 24 months.

Colorectal Cancer Tests (ColorectAlert and ColoPath)

The Company's rectal mucus test (ColorectAlert) is a technology that detects a carbohydrate marker associated with cancerous and pre-cancerous conditions. The ColorectAlert test detects the presence of a specific sugar in the rectal mucus of individuals that may have colorectal cancer or potentially precancerous polyps. This sugar is detected by a chemical reaction performed on a specimen placed on a test membrane following routine digital rectal examinations and does not require a blood sample. The same technology is being adapted for the detection of lung cancer and breast cancer, and could potentially be adapted for the detection of additional cancers.

A second colorectal cancer test, ColoPath, is a technology that detects another marker associated with cancer of the colon or rectum. The technology was developed by Procyon BioPharma Inc. ColoPath is a similar assay to ColorectAlert and is being evaluated in conjunction with the ColorectAlert test.

Lung Cancer Test (LungAlert)

LungAlert is based on a modified version of the ColorectAlert technology, using a sputum sample instead of a rectal mucus sample. The Company undertook a blinded study examining LungAlert in a population with healthy patients, patients with benign lung disease and patients with cancer. LungAlert detected 20 of 23 cancers. The LungAlert Smokers' Study was conducted to determine LungAlert's effectiveness in detecting early stage cancers, particularly in smokers, and to establish the relationship between LungAlert values and the stage and size of tumors. Interim data show that LungAlert's reactivity in sputum samples may be useful as an initial screening test to identify high-risk subjects who would benefit from other tests, such as spiral computed tomography. Patients with cancer had significantly higher values than those who did not.

Breast Cancer Test

The Company's breast cancer test is based on a modified version of the ColorectAlert and LungAlert technology but uses a sample of nipple-aspirate fluid (NAF), which is derived from the mammary ducts and expressed through the nipple. It has developed a prototype of the breast cancer test suitable for clinical evaluation. The Company has tested a small number of samples in a pilot study at the University of Texas M.D. Anderson Cancer Center. This study demonstrated the ability of the test to distinguish between cancerous and non-cancerous breast samples..

Aoxin Tianli Group Inc. (NASDAQ:ABAC) - .

INTELLIGENT MOTOR CR (OTC:ITLL) - .

About BUYINS.NET

BUYINS.NET, http://www.buyins.net, monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS Friction Factor - Market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements" Naked Shorts (RegSho) - Tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING Earnings - Predicts probability, price move and length of move before and after all US stock earnings reports Seasonality - Predicts probability, price move and length of move based on exact time of year for all US stocks Group Correlation - Tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups SqueezeTrigger - Massive database that tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock. Valuation - Tracks all known valuation models and applies them. GATS - Tracks and quantifies known trading strategies by backtesting, optimizing and running genetic algorithms and neural networks to ascertain best trading strategies. PatternScan - Automates tracking of every technical pattern and predicts next move in stocks. Insider - Tracks insiders trading records and determines trading performance. Trades by higher-level insiders are generally more predictive than trades by lower level insiders Events - Tracks patterns directly correlated to specific events.

SqueezeTrigger is a registered trademark, Reg. No. 3,120,641

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. [symbol] has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.

Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net

Contributing Sources

---